Although the treatment potential for PARP inhibitors in wild-type BRCA patients is unknown, both preclinical and in vivo studies are showing promise for their efficacy in breast cancers without BRCA1/2 mutations [77,78,79,80]. Here, BRCA1 is linked to breast carcinoma.